Genmab
Genmab A/S is a Danish biotechnology company specializing in the discovery and development of human antibody therapeutics for oncology treatments. The company leverages proprietary antibody technology platforms, including DuoBody, HexaBody, and Hexect, to generate targeted bispecific antibodies. Revenue is primarily driven by royalty streams from global sales of Darzalex (daratumumab) licensed to Janssen, milestone payments, and commercial sales of co-developed therapies like Epkinly. Key end markets encompass specialized oncology networks, hematology departments, and hospital systems in North America, Europe, and Asia. Genmab holds a leading international market position as an innovator in targeted cancer antibody therapies with multiple commercialized partner drugs. The company is headquartered in Copenhagen, Denmark, and its shares are listed on Nasdaq Copenhagen and Nasdaq in the US under the ticker GMAB.
67 of the funds FundTelligence covers report a position in Genmab.
- Sector
- Health Care
- Country
- Denmark
- Funds holding it
- 67
- Exposure themes
- Cancer, Treatment, Women's Health
Funds holding Genmab
- Nordnet Danmark Indeks — Nordnet · 7.31 % (full portfolio disclosed, October 2026)
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 5.4 % (partially disclosed portfolio, September 2026)
- Nordea Danmark — Nordea Funds · 5.12 % (full portfolio disclosed, September 2026)
- Nordea Danske aktier fokus — Nordea Funds · 4.98 % (full portfolio disclosed, September 2026)
- DNB Fund Women's Health — DNB · 3.21 % (full portfolio disclosed, August 2026)
- Danske Invest Denmark Focus — Danske Invest · 2.99 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 2.48 % (full portfolio disclosed, October 2026)
- DNB Norden — DNB · 2.45 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 67 funds holding it.